[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619259":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":25,"responsibleParty":39,"collaborators":25,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":25,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":25,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":67,"whyStopped":25,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":25},{"fullName":5,"class":6},"Danish Headache Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Pituitary Adenylate Cyclase Activating Polypeptide-38 (PACAP-38)","EXPERIMENTAL","PACAP-38 will be administered by intravenous infusion.",[13],"Drug: Pituitary Adenylate Cyclase Activating Polypeptide-38 (PACAP-38)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo (isotonic saline) will be administered by intravenous infusion.",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","The participants will receive a continuous intravenous infusion of 10 pmol\u002Fkg\u002Fmin PACAP-38 over 20 min",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Haidar Al-Khazali, MD, PhD","CONTACT","+4541598494","halk0007@regionh.dk",{"name":36,"role":32,"phone":37,"phoneExt":25,"email":38},"Hakan Ashina, MD, PhD","+4528102495","haakan.ashina@regionh.dk",{"type":40,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Haidar Al-Khazali","Principal Investigator","100619259","induction-of-migraine-attacks-with-aura-using-pituitary-adenylate-cyclase-activating-polypeptide-38-100619259",false,"NCT07342296","Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38","Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* History of migraine with aura for ≥ 12 months according to the International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria\n* ≥ 1 monthly day with aura that meets criteria as aura on average across the three months before screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures.\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder other than migraine without aura, migraine with aura, chronic migraine, and episodic tension-type headache\n* History or evidence of any other clinically significant disorder, condition, or disease (except for those outlined above) that, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion\n* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start\n* Aura within 48 hours of infusion start","ALL","18 Years","65 Years",{"count":54,"type":55},21,"ESTIMATED","INTERVENTIONAL",[58],"NA","Pituitary Adenylate Cyclase Activating Polypeptide-38 (PACAP-38) is a key neuropeptide in migraine pathophysiology and treatment. This study investigates whether PACAP-38 administration can trigger aura in individuals with a diagnosis of migraine with aura.",[61,62],"Migraine With Aura","Migraine Aura",[64,65,66],"migraine","aura","Pituitary Adenylate Cyclase Activating Polypeptide-38","NOT_YET_RECRUITING","2026-01-08",{"date":70,"type":71},"2026-01-15","ACTUAL",{"date":73,"type":55},"2026-02-01",{"date":75,"type":55},"2026-12-30",{"name":5,"class":6}]